ABSTRACT Aim: The aim of this study was to develop an algorithm to prompt early clinical suspicion of mucopolysaccharidosis type I (MPS I).
INTRODUCTION
Studies have shown that the diagnosis and treatment of mucopolysaccharidosis type I (MPS I) is substantially delayed and that the time between the onset of symptoms and diagnosis has not improved (1) . This diagnostic delay is particularly prominent in patients with attenuated forms of MPS I, with an estimated gap between symptom onset and diagnosis ranging from two to nine years (1) (2) (3) . Given the progressive and multi-systemic nature of this inherited genetic disease, diagnosis should be established as early as possible in the disease course for patients to receive optimal benefit from treatment.
Abbreviations
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Key notes
Our aim was to develop an algorithm to prompt early clinical suspicion of mucopolysaccharidosis type I (MPS I). We convened a working party of 11 experts in paediatrics, rare diseases and inherited metabolic diseases who developed the algorithm, based on key signs and symptoms. The algorithm was tested on 35 patients, and 91% would have been referred earlier if the algorithm had been used.
Although effective newborn screening techniques are now available to facilitate early diagnosis, newborn screening is not yet widely available and there are no biomarkers that can predict phenotypic severity in those newborn infants identified by screening (4) (5) (6) . In some cases, the clinical phenotype could be predicted by the genotype, based on mutations of the human alpha-L-iduronidase gene.
Importance of early diagnosis
Depending on the healthcare system, the first physician to see a patient could be a general practitioner and/or a paediatrician, and greater awareness could lead to a prompt specialist referral (7) . In general, multi-systemic and progressive signs and symptoms should raise suspicion of a genetic disorder, including a lysosomal storage disorder such as MPS I (8) . The benefits of early treatment with haematopoietic stem cell transplantation (HSCT) in patients with severe MPS I include substantial changes in the disease course along with improved cognition (9) (10) (11) . Early treatment of patients with MPS I can also slow disease progression and improve patient outcomes, including quality of life (12) . Sibling studies have suggested that early initiation of treatment with enzyme replacement therapy substantially modifies the disease course in patients with attenuated MPS I (13) (14) (15) . Furthermore, enzyme replacement therapy is recommended once diagnosis is confirmed (16) . Finally, early diagnosis allows for early genetic counselling and informed family planning.
Existing treatments
Haematopoietic stem cell transplantation before 2.5 years of age is the recommended treatment for patients diagnosed with the most severe form of MPS I, the Hurler phenotype (16) . In these patients, allogeneic HSCT stabilises cognitive skills, normalises liver and spleen volume, improves survival (17) , reduces ventricular hypertrophy and maintains cardiac function (18) . Individual patients with an intermediate phenotype may also be considered for HSCT if the benefits outweigh the risks and an optimal donor is available (16) .
Enzyme replacement therapy with recombinant human alpha-L-iduronidase, also known as laronidase, is the specific treatment for patients with the attenuated disease phenotype who do not undergo HSCT (16) . This treatment is also recommended for all diagnosed MPS I patients who have not yet received HSCT or whose graft has failed (16) . Evidence from the literature has suggested that early treatment initiation is associated with better outcomes. A retrospective analysis of nine sibling cases with attenuated MPS I suggested that initiation of laronidase prior to symptom onset slowed or prevented the development of severe clinical manifestations (13) . In a large cohort of patients with attenuated MPS I, treatment with laronidase resulted in disease stabilisation in the majority of patients after a mean follow-up of 6.1 years (19) .
Clinical profile of MPS I
In patients with severe MPS I, symptom onset occurs in the first months of life and the disease progresses more rapidly than in the attenuated form. Common signs and symptoms include kyphosis or gibbus, developmental delay, hernias, coarse facial features, corneal clouding, cardiac valve abnormalities, hepatomegaly (1) and airway-related symptoms (20) .
In patients with attenuated MPS I, presenting symptoms that may seem innocuous often become important as the disease progresses and these should therefore prompt suspicion of MPS I. They include hernias, cardiac valve abnormalities, recurrent ear, nose and throat (ENT) infections, joint contractures or stiffness, coarse facial features, corneal clouding and carpal tunnel syndrome (3, 21) . Other frequently occurring symptoms, including hepatomegaly, hearing loss and changes in hair morphology (22, 23) , may be revealed by a meticulous medical history and complete physical examination of all the organ systems that are potentially affected by the disease.
Until newborn screening programmes and early phenotypic biomarkers of phenotypes are universally available, it is very important that physicians become more aware of the early clinical signs and symptoms of MPS I.
The aim of this study was to develop an algorithm to prompt early clinical suspicion of MPS I by bringing together an international group of experts in this field.
METHODS

Consensus process and rationale
An international working group of 11 experts met in 2016 to reach a consensus on an algorithm to prompt early clinical suspicion of MPS I. The working group represented experts in paediatrics, rare diseases and inherited metabolic diseases from nine countries: Poland, Belgium, Italy, United Arab Emirates, France, Germany, Denmark, The Netherlands and Czech Republic.
The algorithm was drafted during two one-day meetings. During the first meeting, the experts shared their experience based on real-world clinical cases in an attempt to identify the signs and symptoms that contribute to a standard clinical profile, both the key early referral signs and symptoms and the less specific but common signs and symptoms. Based on this information, they drafted an algorithm to help physicians recognise MPS I and refer patients to metabolic disease specialists in a timely manner. The experts then collected data from the clinical records of their most recently diagnosed MPS I patients. These data were used during the second meeting to refine the draft algorithm. Another set of data, from the patient cohort used to draft the first version of the algorithm, was subsequently collected to investigate the age when specific signs and symptoms were first recognised by the relevant healthcare professional and noted in the patients' medical records. This information was used to reconstruct the patients' natural history, and then, the algorithm was finalised and It is characterised by an enlargement of the liver and is often associated with an enlargement of the spleen. This is one of the most common, less-specific presenting signs across all MPS I phenotypes and could aid in early referral in combination with another less-specific sign or symptom. Cardiac valve disease Expert comments Cardiac abnormalities are common early signs that do not lead to further investigation. Abnormalities in cardiac valves are present in all patients, but are rarely reported before diagnosis. However, these symptoms can lead to later heart failure. Information from the literature Heart disease is particularly frequent and rapidly progressing (3, 26, 27 Expert comments Unexplained hearing loss should alert the physician to look for other symptoms or signs suggestive of MPS I. Such hearing loss may not be present at onset, but rather develops over the course of the disease.
Recurrent orthopaedic or ENT surgeries Expert comments
When recurrent surgeries present with other less-specific signs and symptoms, this can help with the early referral of patients.
the experts reached a consensus based on this information. Table 1 shows the key signs and symptoms that were selected on the basis of their prevalence and specificity, considering the natural history data analysed.
RESULTS
Developing the algorithm
The proposed algorithm to prompt early clinical suspicion of MPS I and expedite referral to an appropriate It manifests mostly as a loss of fine motor functions together with usual associated symptoms such as night-time pain, numbness, tingling or burning sensation (12, 21) . Carpal tunnel syndrome-related surgeries account for 5% of all reported surgeries and are the most common surgeries for the Scheie phenotype accounting for 43% of cases (24) . specialist is shown in Figure 1 . Highly specific signs and symptoms that prompt seeking medical advice were identified as the first clinical features for consideration. Clusters of less-specific signs and symptoms were considered on the basis of their frequency, in combination with the most common specific signs and symptoms. Finally, age at presentation was included, as it could help to differentiate between the different forms of MPS I. Joint stiffness without inflammation and kyphosis or gibbus are highly specific presenting signs and symptoms that, on their own, are sufficient to raise suspicion of MPS I and prompt referral to a specialised centre for MPS testing (Fig. 2) . A combination of two or more less-specific signs and symptoms should also prompt referral to a specialised centre for further MPS testing. These include recurrent hernias, recurrent ENT infections, growth velocity decline, coarse facial features or facial dysmorphism, cardiac valve disease, developmental delay, recurrent orthopaedic or ENT surgery, hepatomegaly, carpal tunnel syndrome, corneal clouding and hearing loss that cannot be explained by an ear infection. The patient should be referred to the metabolic or genetic specialist without delay, even if just on the basis of a suspicion of MPS I. If available, urinary glycosaminoglycan testing may be performed to facilitate the diagnosis of MPS. However, as false-negative results may be obtained depending on the technique used, careful interpretation of the urinary glycosaminoglycan testing results is required to avoid delays in diagnosis.
When referring to this algorithm, several points need to be considered. First, as 6000-8000 different rare diseases have been identified, 75% of which manifest in childhood (30), it is not realistic to expect paediatricians and general practitioners to know about the specific signs or symptoms related to each disorder or to be able to use algorithms that may lead to an early diagnosis of every disorder. However, as MPS I is a treatable disease and timely initiation of therapy is paramount, early recognition and referral to the appropriate specialists should be prompted. The presented algorithm aims to increase the knowledge of paediatricians and general practitioners about the cluster of early signs and symptoms of MPS I, which could lead to timely collaboration with a metabolic disease specialist, a clinical geneticist or another specialist with expertise in the management of rare genetic disorders and thus achieve an optimal outcome for the patient. Second, the algorithm should be tailored according to the healthcare system in the individual countries, as different medical specialists may be using this algorithm. Lastly, if urinary glycosaminoglycan test results are negative, but the patient demonstrates other convincing symptoms of MPS, the healthcare physician should seek an appropriate referral for the patient. 
DISCUSSION
Mucopolysaccharidosis type I is a multi-organ, progressive disorder for which effective treatments are now available. Newborn screening for MPS I is starting to be included in newborn screening programmes, but until newborn screening is universally available, it is imperative that healthcare practitioners do not miss early opportunities for diagnosis. The benefits of timely and appropriate treatment are optimised with early diagnosis and include the prevention of irreversible organ damage, reduction of complications, possible improvement of quality of life, avoidance of unnecessary surgeries and treatments, mitigation of detrimental impacts on the patient and his or her family arising through uncertainty, the social aspects of an undiagnosed illness and family planning and counselling. These benefits highlight the need to evoke clinical suspicion of MPS I in patients who present with key clinical features of kyphosis or gibbus, or joint stiffness or contractures without inflammation and to better educate paediatricians, general practitioners and other specialists about the disease. In this regard, evaluating symptom and sign clusters rather than individual signs could assist in the early diagnosis of MPS I. Data from an observational study published in 2017 provided further support for using selected signs and symptoms to prompt suspicions of MPS, including MPS I, and the important role paediatricians play in facilitating an early diagnosis (31) . Limitations of the algorithm included the limited number of patients in each subgroup and the retrospective nature of the testing, which was only performed on data from patients with confirmed MPS I.
CONCLUSION
A working group of international experts used data from real-world clinical cases, together with data from published literature, to define the natural history of MPS I across the phenotypic spectrum. The proposed diagnostic algorithm that they have developed not only raises awareness of MPS I, but more importantly empowers individual physicians to identify potential cases and thus improve early diagnosis. Furthermore, the proposed algorithm is intended to shorten the interval between the first healthcare contact with the patient with symptoms and signs suggestive of MPS I and the final diagnosis with the overarching objective of improving outcomes for patients with this progressive, yet treatable disorder. In this regard, the role of the medical specialist, who is often a paediatrician or general practitioner, is of paramount importance for the timely recognition of suspected cases and collaboration with an appropriate specialist to ensure optimal outcomes. Continuous efforts are needed to engage the specialists involved in the primary care of these patients and to establish a referral network.
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